Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Clinical significance and pro-oncogenic function of DBF4 in clear cell renal cell carcinoma.
BMC Urol
January 2025
Institute of Clinical Medicine, The Second affiliated Hospital of Hainan Medical University, 368th Yehai Avenue, Haikou, Hainan, 570311, China.
Background: Clear cell renal cell carcinoma (ccRCC) is the most common malignant urological tumor, and regrettably, and is insensitive to chemotherapy and radiotherapy, resulting in poor patient outcomes. DBF4 plays a critical role in DNA replication and participates in various biological functions, making it an attractive target for cancer treatment. However, its significance in ccRCC has not yet been explored.
View Article and Find Full Text PDFManaging risk factors and early intervention for chronic kidney disease.
Nat Rev Nephrol
January 2025
Renal Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
A network meta-analysis of therapies for hyperphosphatemia in CKD based on randomized trials.
Sci Rep
January 2025
College of Traditional Chinese Medicine, Shandong Second Medical University, Weifang, China.
To update the efficacy and safety of different drugs for the treatment of patients with hyperphosphatemia in chronic kidney disease, we conducted a network meta-analysis of 22 therapies for the treatment of uncontrolled hyperphosphatemia in patients with chronic kidney disease (CKD). All randomized controlled trials on hyperphosphatemia published from January 2013 to November 2023 were searched from CNKI, VIP database, Wanfang database, PubMed, Scopus, and Cochrane databases. Meta-analysis was used to evaluate the serum phosphorus, calcium levels, total effective rate and adverse events of patients with chronic kidney disease (CKD).
View Article and Find Full Text PDFInitial Decline in Glomerular Filtration Rate With Finerenone in HFmrEF/HFpEF: A Prespecified Analysis of FINEARTS-HF.
J Am Coll Cardiol
January 2025
British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, United Kingdom. Electronic address:
Background: An initial decline in estimated glomerular filtration rate (eGFR) often leads to reluctance to continue life-saving therapies in patients with heart failure (HF).
Objectives: The goal of this study was to describe the association between initial decline in eGFR and subsequent clinical outcomes in patients randomized to placebo or finerenone.
Methods: In this prespecified analysis of FINEARTS-HF (Finerenone Trial to Investigate Efficacy and Safety Superior to Placebo in Patients with Heart Failure), we examined the association between initial decline in eGFR (≥15%) from randomization to 1 month and subsequent outcomes in patients assigned to finerenone or placebo.
Risk of Vertebral Fracture in Individuals with End-Stage Renal Disease Secondary to Vasculitis.
Kidney360
January 2025
Department of Medicine, Medical College of Georgia, Augusta University, Augusta, GA, USA.
Background: Glucocorticoids are central to vasculitis treatment but increase vertebral fracture risk. This study assessed whether vasculitis as the cause of ESRD is associated with incident vertebral fracture, controlling for corticosteroid use.
Methods: A retrospective cohort study was conducted from 2006-2019 on adults in the U.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!